S&P Futures
5,886.25 -10.00 (-0.17%) Dow Futures
43,121.00 -56.00 (-0.13%) Nasdaq Futures
20,472.50 -47.00 (-0.23%) Russell 2000 Futures
2,249.80 -5.70 (-0.25%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,747.90 +9.00 (+0.33%)
NKGen Biotech, Inc. (NKGN)
After hours:
- GlobeNewswire
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from Octo
- GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
SANTA ANA, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced upcoming poster presentations on a final report of a Phase 1 dose escalation study and on a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in subjects with Alzheime
